Arrowhead Pharmaceuticals (ARWR) news
Recent news
Arrowhead's Aro-Mapt cuts tau up to 73% in phase 1/2A
Arrowhead Pharmaceuticals has reported preliminary data from its phase 1/2a clinical trial for ARO-MAPT, an RNA interference therapy targeting the MAPT gene responsible for producing tau protein. The trial demonstrated reduction in tau levels of up to 73% in participants, marking a significant…
AInvest Wire · 20h agoArrowhead's trim platform achieves clinical validation
Arrowhead Pharmaceuticals has announced that its TRIM (Targeted RNA Interference Mediated) platform has achieved clinical validation, marking a significant milestone in the company’s research and development efforts. The platform, which enables the delivery of RNA interference therapeutics to…
AInvest Wire · 20h agoArrowhead Pharmaceuticals - Aro-mapt generally well tolerated, most adverse events mild, no serious teaes reported
AInvest Wire · 20h agoArrowhead Pharmaceuticals - To complete dosing in healthy volunteers, data updates expected in 2027
AInvest Wire · 20h agoArrowhead Pharmaceuticals announces aro-mapt interim phase 1/2A clinical data demonstrating deep and durable tau reductions in healthy volunteers
AInvest Wire · 20h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.